Why Is Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Up 136.4% Today?

Apellis Pharmaceuticals (APLS) stock ripped 136.4% higher to $40.395 on Tuesday, March 31, 2026, on explosive volume of 25,950,272 shares—11.8 times the 30-day average of 2.2M. The stock opened at $17.09 and printed intraday lows near $40.35 before closing near session highs, a classic capitulation-to-squeeze reversal. The catalyst: a reported $193 million strategic investment bet targeting APLS's complement-inhibition platform and turnaround potential amid $689 million in annual revenue.

What's Driving APLS Stock Up 136.4% Today

The primary catalyst is a $193 million strategic investment into Apellis, reported by The Motley Fool on March 21, 2026, but apparently gaining traction with institutional buyers today. This bet validates the company's complement-inhibition platform—a mechanism targeting the immune system's complement cascade for diseases with significant unmet medical needs.

Apellis operates as a commercial-stage biopharmaceutical company with established revenue ($689M annualized) and an expanding clinical pipeline. The $193M injection is not typical venture financing; it suggests a strategic partner (likely a larger pharma or specialty biotech) is betting on APLS's commercial execution and pipeline potential. This type of external validation often triggers short covering and fresh institutional buying.

The volume spike—11.8x average—confirms this was a forced squeeze. With 25.95M shares trading in a single day versus a typical 2.2M, short sellers likely capitulated, buying back positions into strength. The tight $40.35 to $40.45 intraday range on massive volume is textbook capitulation: shorts covering into the bid with minimal resistance, causing the stock to "print" at higher levels with each buyback.

APLS Stock Key Levels to Watch

APLS is now trading at $40.395, a move from its previous close of $17.09. This marks the highest level in recent memory for the stock, shattering prior resistance.

Support levels to monitor:

• $30–$32: Initial support on any pullback; represents a 25% retreat from today's close yet still a 76% gain from yesterday's open.
• $25–$27: Secondary support; aligns with pre-announcement levels before the $193M bet became public knowledge.
• $17.09: Yesterday's close; would represent a full reversal, though extremely unlikely given the fundamental catalyst.

Resistance above $40.39 is untested. The stock's 50-day and 200-day moving averages are likely far below current price due to the historical underperformance of APLS shares. Watch for gravity toward the 50-day MA around $22–$26 if profit-taking accelerates; the 200-day MA is probably near $18–$20.

What Analysts Say About APLS Stock

Recent analyst actions reflect institutional enthusiasm for APLS's strategic positioning. At the JP Morgan Healthcare Conference on January 12, 2026, Apellis highlighted "commercial execution and strategic priorities," messaging that likely resonated with sell-side analysts evaluating pipeline depth and commercial viability.

Consensus ratings prior to today's move likely ranged from Hold to Buy, with price targets in the $25–$35 range (now clearly too conservative). The $193M investment effectively forces analyst target revisions upward; any analyst maintaining a $25–$30 target post-investment announcement will face credibility pressure.

Based on today's $2.2B market cap and the company's $689M annual revenue, APLS is trading at approximately 3.2x sales—a reasonable multiple for a commercial-stage biotech with an expanding pipeline. If analysts model 15–20% revenue growth over the next three years (achievable for complement-inhibitor specialists), the current valuation becomes increasingly attractive on a forward earnings basis.

What's Next for Apellis Stock

Immediate catalysts: Q1 2026 earnings results and conference call (date TBD, likely late April or early May). Management must articulate how the $193M investment will accelerate pipeline progression, expand commercial infrastructure, or fund new indications.

Bull case: The $193M bet represents a floor valuation; if a strategic partner is willing to invest at this valuation, it suggests APLS's complement-inhibitor therapies are tracking ahead of previous expectations. Continued clinical wins, expanded label approvals, or acquisition interest could push the stock to $55–$65 within 12 months.

Bear case: This move is likely overextended on speculation. Profit-taking could accelerate above $40, pulling the stock back toward $28–$32 within 2–4 weeks. Biotech remains volatile; any negative trial data, FDA feedback, or leadership changes could trigger sharp reversals. Investors should monitor insider selling and dilution from the $193M raise.

Key event to watch: Q1 2026 earnings call (timing TBD, expected late April/early May 2026). Management's guidance on revenue trajectory, pipeline advancement, and use of proceeds will determine whether today's move is justified or a speculative bubble.

Frequently Asked Questions

Why is APLS stock up 136.4% today?
A $193 million strategic investment into Apellis Pharmaceuticals signaled renewed confidence in its complement-inhibitor platform and commercial execution. The stock surged on 11.8x average volume, driven by short covering and fresh institutional buying following the investment announcement.

Is APLS stock a buy at $40.39?
That depends on your risk tolerance and investment horizon. At 3.2x sales with an expanding pipeline and external validation via the $193M investment, the stock is arguably less risky than before. However, biotech volatility is extreme; this level represents a parabolic move from $17.09, and profit-taking is common. Check recent APLS stock page analyst ratings before making any decision.

What is APLS stock's price target?
Prior analyst targets are now outdated due to today's move. Expect revisions upward in the coming days. Watch for new targets in the $45–$55 range as analysts model the impact of the $193M investment.

What does Apellis Pharmaceuticals do?
Appellis is a commercial-stage biopharmaceutical company specializing in complement-system inhibition—targeting the immune system's complement cascade to treat diseases with high unmet medical needs. The company generates approximately $689 million in annual revenue.

When is the next earnings report?
Q1 2026 earnings results are expected in late April or early May 2026. This will be the critical catalyst to validate today's move. Monitor the earnings calendar for the exact date.

The Bottom Line

APLS's 136.4% surge on 11.8x volume reflects institutional re-rating of a company previously trading at distressed valuations. The $193 million strategic investment provides external validation of the complement-inhibitor platform and commercial strategy. At $40.39 with a $2.2B market cap, the stock is no longer a deep-value play—it's now a growth story dependent on pipeline execution and continued commercial traction. The real test comes when Q1 2026 earnings reveal whether management can capitalize on this momentum and justify the elevated valuation. Until then, expect volatility as profit-takers test support and new money evaluates whether $40+ is fair value or a speculative peak.

For deeper insights into how biotech stocks move on clinical announcements and strategic investments, explore our market news section for additional coverage of pharmaceutical sector catalysts.